Pharma

World EPA Congress 2027

Evidence, Pricing and Access is Europe’s largest congress in market access, pricing and evidence featuring 250 speakers, multiple streams and over 1500 attendees from pharma, biotech and Payers/ HTA’s.

Visit the official site
71Speakers
0Sponsors
1Exhibitors
66On the bill · sessions
65Companies · in total
§I

Speakers

Programmed at World, in alphabetical order.
Adam PARNABY
Lead, Global Policy & Access · Bristol Myers Squibb
Adriana Robayo
Executive Director · Instituto de Evaluacin Tecnolgica en Salud (IETS)
Alessandro Monaco
General Manager · Oliba Healthcare and Pharma
Alexander Natz
Secretary General · EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Alex Bastian
Vice President, Commercial Strategy · Memo Therapeutics
Amy Israel
Senior Advisor, Access to Medicines · Union for International Cancer Control
Ana Filipa Alexandre
Senior Director, Pipeline Head for Neuroscience · Teva Pharmaceuticals
Anh Bourcet Nguyen
International Director, Government Affairs and Policy, Rare Diseases · AstraZeneca
Anna Vicere
Director, Access Policy & Public Affairs · Vaccines Europe
Anne Willemsen
Chair JCA Subgroup · Zorginstituut Nederland
Antonella Cardone
CEO · Cancer Patients Europe
Aveline Godard
Head of Global Pricing & Tendering · Ferring
Ayman Semaan
Head of Market Access & Pricing · Biologix
Brad Groves
Director, NICE Advice · National Institute for Health & Care Excellence (NICE)
Bruno Cherel
Senior Director, Head of Pricing · Jazz Pharmaceuticals
Caroline van der Meijden
Director · iMTA
Christoph Glaetzer
Chief Global Value and Access Officer · Johnson & Johnson Innovative Medicine
Elizabeth Kinter
Vice President, Head of Global Market Access · Avidity BioSciences
Emanuele Marsili
Global Access Lead · CSL
Eva Susanne Dietrich
Professor, Departments for Clinical Pharmacy and Regulatory Affairs · University of Bonn
Fabienne Bartoli
Inspector General · French National Authority for Health
Gavin Lewis
Senior Vice President, Head of Value and Access · Novartis
§III

Agenda

Selected from 66 sessions on the bill.
  • Mar 2 10:20

    Keynote: Reframing evidence planning for rare diseases in the JCA era - TBC

    Plenary
  • Mar 2 10:40

    Keynote: Access by design: Embedding access into core development decisions - TBC

    Plenary
  • Mar 2 12:15

    Chair's opening remarks

    Track 1 (Market Access)
  • Mar 2 12:20

    Actionable Frameworks for Rapid Market Access Planning

    Track 1 (Market Access)
  • Mar 2 12:20

    AI-Enabled automation of evidence synthesis for modelling and value dossiers: SLR, feasibility assessment, ITC, and medical writing - TBC

    Track 8 (Artificial Intelligence & Data)
  • Mar 2 12:20

    AI will decide who gets access: why drug contracting is becoming pharma’s most strategic capability - TBC

    Track 6 (Reimbursement)
  • Mar 2 12:20

    Anchoring evidence-based decisions in a volatile policy landscape: strategic considerations for EU HTAR - TBC

    Track 5 (Real World Evidence & Data)
  • Mar 2 12:20

    Clearing the fog: A practical guide to EUHTA JCA & expected Country P&R Processes - TBC

    Track 9 (HEOR)
  • Mar 2 12:20

    From JSC to HTA: early decisions that shape price and access success

    Track 2 (HTA)
Intermission
Part the Second · For the Buyer

An audience of 65 companies, parsed from the program.

65 companies in attendance.

The numbers below are derived from the speakers, sponsors, and exhibitors on this page, cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.

Who's in the room
0All threespeak · spons · exh
0Sponsoringsponsor only
1Exhibitingexhibitor only
64Companies Speakingspeaker only
Speakers by seniority

62% of the speakers carry senior titles: C-suite, Founder, VP, or Director-level.

  • C-suite57%
  • VP-level1014%
  • Director / Head of2941%
  • Manager / Lead68%
  • Engineer · IC11%
  • Research / Science11%
  • Advisor / Investor23%
  • Other roles1724%

Of 71 on the bill · classified by free-text title

Most-represented companies
  1. 01Takeda3V
  2. 02Agency for Health Technology Assessment and Tariff System2V
  3. 03CombinaticsEx
  4. 04G-BA2V
  5. 05Jazz Pharmaceuticals2V
  6. 06Office of Health Economics2V
  7. 07UCB2V
  8. 08Access to Medicine Foundation1V
  9. 09ADVANZ PHARMA1V
  10. 10Alliance for Regenerative Medicine1V
  11. 11Alnylam Pharmaceuticals1V
  12. 12AOTMiT1V
  13. 13Astellas1V
  14. 14AstraZeneca1V
Sponsors by tier

Tiers were not disclosed for this event.